Skip to main content
. 2018 Apr 18;29(6):1461–1467. doi: 10.1093/annonc/mdy118

Figure 2.

Figure 2.

Proportion of subjects with ≥ 1 SBM (A) or ≥ 1 CSBM (B) at specific time points within 24 h after the initial dose of the study drug in COMPOSE-4 (proportion ± 95% CI; FAS). *P < 0.0001 versus placebo. CI, confidence interval; CSBM, complete spontaneous bowel movement; FAS, full analysis set; SBM, spontaneous bowel movement.